Cargando…
COVID-19 antibody seroprevalence in Santa Clara County, California
BACKGROUND: Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara Co...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928865/ https://www.ncbi.nlm.nih.gov/pubmed/33615345 http://dx.doi.org/10.1093/ije/dyab010 |
_version_ | 1783659900057944064 |
---|---|
author | Bendavid, Eran Mulaney, Bianca Sood, Neeraj Shah, Soleil Bromley-Dulfano, Rebecca Lai, Cara Weissberg, Zoe Saavedra-Walker, Rodrigo Tedrow, Jim Bogan, Andrew Kupiec, Thomas Eichner, Daniel Gupta, Ribhav Ioannidis, John P A Bhattacharya, Jay |
author_facet | Bendavid, Eran Mulaney, Bianca Sood, Neeraj Shah, Soleil Bromley-Dulfano, Rebecca Lai, Cara Weissberg, Zoe Saavedra-Walker, Rodrigo Tedrow, Jim Bogan, Andrew Kupiec, Thomas Eichner, Daniel Gupta, Ribhav Ioannidis, John P A Bhattacharya, Jay |
author_sort | Bendavid, Eran |
collection | PubMed |
description | BACKGROUND: Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara County. METHODS: On 3 and 4 April 2020, we tested 3328 county residents for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to SARS-CoV-2 using a rapid lateral-flow assay (Premier Biotech). Participants were recruited using advertisements that were targeted to reach county residents that matched the county population by gender, race/ethnicity and zip code of residence. We estimate weights to match our sample to the county by zip, age, sex and race/ethnicity. We report the weighted and unweighted prevalence of antibodies to SARS-CoV-2. We adjust for test-performance characteristics by combining data from 18 independent test-kit assessments: 14 for specificity and 4 for sensitivity. RESULTS: The raw prevalence of antibodies in our sample was 1.5% [exact binomial 95% confidence interval (CI) 1.1–2.0%]. Test-performance specificity in our data was 99.5% (95% CI 99.2–99.7%) and sensitivity was 82.8% (95% CI 76.0–88.4%). The unweighted prevalence adjusted for test-performance characteristics was 1.2% (95% CI 0.7–1.8%). After weighting for population demographics, the prevalence was 2.8% (95% CI 1.3–4.2%), using bootstrap to estimate confidence bounds. These prevalence point estimates imply that 53 000 [95% CI 26 000 to 82 000 using weighted prevalence; 23 000 (95% CI 14 000–35 000) using unweighted prevalence] people were infected in Santa Clara County by late March—many more than the ∼1200 confirmed cases at the time. CONCLUSION: The estimated prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that COVID-19 was likely more widespread than indicated by the number of cases in late March, 2020. At the time, low-burden contexts such as Santa Clara County were far from herd-immunity thresholds. |
format | Online Article Text |
id | pubmed-7928865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79288652021-03-04 COVID-19 antibody seroprevalence in Santa Clara County, California Bendavid, Eran Mulaney, Bianca Sood, Neeraj Shah, Soleil Bromley-Dulfano, Rebecca Lai, Cara Weissberg, Zoe Saavedra-Walker, Rodrigo Tedrow, Jim Bogan, Andrew Kupiec, Thomas Eichner, Daniel Gupta, Ribhav Ioannidis, John P A Bhattacharya, Jay Int J Epidemiol Covid-19 BACKGROUND: Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara County. METHODS: On 3 and 4 April 2020, we tested 3328 county residents for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to SARS-CoV-2 using a rapid lateral-flow assay (Premier Biotech). Participants were recruited using advertisements that were targeted to reach county residents that matched the county population by gender, race/ethnicity and zip code of residence. We estimate weights to match our sample to the county by zip, age, sex and race/ethnicity. We report the weighted and unweighted prevalence of antibodies to SARS-CoV-2. We adjust for test-performance characteristics by combining data from 18 independent test-kit assessments: 14 for specificity and 4 for sensitivity. RESULTS: The raw prevalence of antibodies in our sample was 1.5% [exact binomial 95% confidence interval (CI) 1.1–2.0%]. Test-performance specificity in our data was 99.5% (95% CI 99.2–99.7%) and sensitivity was 82.8% (95% CI 76.0–88.4%). The unweighted prevalence adjusted for test-performance characteristics was 1.2% (95% CI 0.7–1.8%). After weighting for population demographics, the prevalence was 2.8% (95% CI 1.3–4.2%), using bootstrap to estimate confidence bounds. These prevalence point estimates imply that 53 000 [95% CI 26 000 to 82 000 using weighted prevalence; 23 000 (95% CI 14 000–35 000) using unweighted prevalence] people were infected in Santa Clara County by late March—many more than the ∼1200 confirmed cases at the time. CONCLUSION: The estimated prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that COVID-19 was likely more widespread than indicated by the number of cases in late March, 2020. At the time, low-burden contexts such as Santa Clara County were far from herd-immunity thresholds. Oxford University Press 2021-02-22 /pmc/articles/PMC7928865/ /pubmed/33615345 http://dx.doi.org/10.1093/ije/dyab010 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Covid-19 Bendavid, Eran Mulaney, Bianca Sood, Neeraj Shah, Soleil Bromley-Dulfano, Rebecca Lai, Cara Weissberg, Zoe Saavedra-Walker, Rodrigo Tedrow, Jim Bogan, Andrew Kupiec, Thomas Eichner, Daniel Gupta, Ribhav Ioannidis, John P A Bhattacharya, Jay COVID-19 antibody seroprevalence in Santa Clara County, California |
title | COVID-19 antibody seroprevalence in Santa Clara County, California |
title_full | COVID-19 antibody seroprevalence in Santa Clara County, California |
title_fullStr | COVID-19 antibody seroprevalence in Santa Clara County, California |
title_full_unstemmed | COVID-19 antibody seroprevalence in Santa Clara County, California |
title_short | COVID-19 antibody seroprevalence in Santa Clara County, California |
title_sort | covid-19 antibody seroprevalence in santa clara county, california |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928865/ https://www.ncbi.nlm.nih.gov/pubmed/33615345 http://dx.doi.org/10.1093/ije/dyab010 |
work_keys_str_mv | AT bendavideran covid19antibodyseroprevalenceinsantaclaracountycalifornia AT mulaneybianca covid19antibodyseroprevalenceinsantaclaracountycalifornia AT soodneeraj covid19antibodyseroprevalenceinsantaclaracountycalifornia AT shahsoleil covid19antibodyseroprevalenceinsantaclaracountycalifornia AT bromleydulfanorebecca covid19antibodyseroprevalenceinsantaclaracountycalifornia AT laicara covid19antibodyseroprevalenceinsantaclaracountycalifornia AT weissbergzoe covid19antibodyseroprevalenceinsantaclaracountycalifornia AT saavedrawalkerrodrigo covid19antibodyseroprevalenceinsantaclaracountycalifornia AT tedrowjim covid19antibodyseroprevalenceinsantaclaracountycalifornia AT boganandrew covid19antibodyseroprevalenceinsantaclaracountycalifornia AT kupiecthomas covid19antibodyseroprevalenceinsantaclaracountycalifornia AT eichnerdaniel covid19antibodyseroprevalenceinsantaclaracountycalifornia AT guptaribhav covid19antibodyseroprevalenceinsantaclaracountycalifornia AT ioannidisjohnpa covid19antibodyseroprevalenceinsantaclaracountycalifornia AT bhattacharyajay covid19antibodyseroprevalenceinsantaclaracountycalifornia |